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Abstract 
Background: The latent reservoir in resting CD4+ T cells presents a major barrier to HIV cure. Latency-reversing 
agents are therefore being developed with the ultimate goal of disrupting the latent state, resulting in induction 
of HIV expression and clearance of infected cells. Histone deacetylase inhibitors (HDACi) have received a significant 
amount of attention for their potential as latency-reversing agents.
Results: Here, we have investigated the in vitro and systemic in vivo effect of panobinostat, a clinically relevant 
HDACi, on HIV latency. We showed that panobinostat induces histone acetylation in human PBMCs. Further, we 
showed that panobinostat induced HIV RNA expression and allowed the outgrowth of replication-competent virus 
ex vivo from resting CD4+ T cells of HIV-infected patients on suppressive antiretroviral therapy (ART). Next, we demon-
strated that panobinostat induced systemic histone acetylation in vivo in the tissues of BLT humanized mice. Finally, in 
HIV-infected, ART-suppressed BLT mice, we evaluated the effect of panobinostat on systemic cell-associated HIV RNA 
and DNA levels and the total frequency of latently infected resting CD4+ T cells. Our data indicate that panobinostat 
treatment resulted in systemic increases in cellular levels of histone acetylation, a key biomarker for in vivo activity. 
However, panobinostat did not affect the levels of cell-associated HIV RNA, HIV DNA, or latently infected resting CD4+ 
T cells.
Conclusion: We have demonstrated robust levels of systemic histone acetylation after panobinostat treatment of 
BLT humanized mice; and we did not observe a detectable change in the levels of cell-associated HIV RNA, HIV DNA, 
or latently infected resting CD4+ T cells in HIV-infected, ART-suppressed BLT mice. These results are consistent with 
the modest effects noted in vitro and suggest that combination therapies may be necessary to reverse latency and 
enable clearance. Animal models will contribute to the progress towards an HIV cure.
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Background
Antiretroviral therapy (ART) is able to suppress plasma 
viral load in HIV-infected patients to undetectable lev-
els, resulting in a reduction in morbidity and mortality. 
However, these drugs are not able to cure HIV infection, 
so most patients must remain on treatment indefinitely. 
The major barrier to cure is that persistent viral infection 
leads to rebound after ART is interrupted [1]. In addition 
to ongoing replication in lymphoid tissue sanctuary sites 
[2], this persistent infection resides as integrated and 
transcriptionally silent provirus in the genomes of rest-
ing CD4+ T cells [3–8], creating a latent reservoir defined 
as a “reversibly nonproductive state of infection” with the 
“capacity to produce infectious virus particles” [9].
One strategy to cure HIV is to purge the latent reser-
voir through latency reversal followed by the clearance 
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of infected cells [10–12]. Specifically, latency-reversing 
agents (LRAs) would induce HIV RNA transcription and 
viral protein synthesis, followed by death of infected cells 
mediated by viral cytopathic effects, the host immune 
system, or a targeted cytotoxic agent. HIV latency is 
maintained partly by the action of histone deacetylase 
(HDAC) enzymes. Specifically, deacetylation of histones 
contributes to a restricted chromatin environment and to 
transcriptional repression of HIV [13, 14]. To reverse this 
mechanism, HDAC inhibitors (HDACi) have been exten-
sively investigated as potential LRAs [15–19].
In particular, panobinostat (pan-HDAC inhibitor, 
LBH589) has been studied for its ability to disrupt HIV 
latency. Previous studies have shown that panobinostat 
induces HIV expression in latently infected cell line mod-
els like U1 and ACH2 [20], in primary CD4+ T cell mod-
els of latency [20, 21], and in resting CD4+ T cells isolated 
from chronically infected, ART-suppressed patients [22, 
23]. Clinical trials are currently underway in humans 
[24, 25]; and initial results indicate that, although in vivo 
administration of panobinostat resulted in a modest (3.5-
fold) increase of cell-associated HIV RNA in peripheral 
blood, it did not reduce the size of the latent reservoir in 
the panobinostat-treated patients [24].
While HIV cure interventions will ultimately need to 
be proven effective in humans, animal models such as 
rhesus macaques or humanized mice are advantageous 
for preclinical investigation of candidate latency-revers-
ing agents, particularly because of the opportunity to 
analyze multiple tissue samples other than peripheral 
blood. A study in SIVmac239-infected ART-suppressed 
Indian rhesus macaques showed increases in peripheral 
blood cell-associated HIV RNA after administration of 
another HDAC inhibitor vorinostat [26]. In contrast, 
vorinostat did not significantly change viral RNA levels 
in another study of SIVmac251-infected ART-suppressed 
Chinese rhesus macaques [27].
Here, we used bone marrow–liver–thymus (BLT) 
humanized mice to investigate the systemic in vivo effect 
of panobinostat on histone acetylation, cell-associated 
HIV RNA, HIV DNA, and latently infected resting CD4+ 
T cells. BLT mice have been shown to recapitulate key 
features of HIV transmission, infection, pathogenesis, and 
treatment [28–40]. Furthermore, the frequency of latently 
infected resting CD4+ T cells in HIV-infected, ART-sup-
pressed BLT mice has been previously measured using a 
quantitative viral outgrowth assay (QVOA) [41]. In this 
current study, we demonstrated that, despite robust levels 
of systemic histone acetylation after panobinostat treat-
ment, there were no detectable changes in the levels of 
cell-associated HIV RNA, HIV DNA, or latently infected 
resting CD4+ T cells. These results are largely consistent 
with those previously reported in human studies.
Methods
Ethics statement
All animal experiments were conducted following 
guidelines for housing and care of laboratory animals in 
accordance with University of North Carolina at Chapel 
Hill (UNC Chapel Hill) regulations after review and 
approval by the UNC Chapel Hill Institutional Animal 
Care and Use Committee (permit number 12-171). HIV-
infected patients receiving stable, standard-of-care ART 
with plasma HIV-1 RNA <50 copies/ml and a CD4 count 
of >300/µl for at least 6 months were enrolled following 
informed consent. Studies were approved by the UNC 
Chapel Hill institutional biomedical review board and the 
Food and Drug Administration.
Isolation of resting human CD4+ T cells for RNA induction 
and quantitative viral outgrowth assay
Mononuclear cells were isolated from patient leuka-
pheresis products or were pooled from the peripheral 
blood, lymph nodes, bone marrow, spleen, liver, lung, 
and thymic organoid of each mouse (one mouse =  one 
pooled sample). Samples from humanized mice were 
first enriched for human cells using an EasySep Mouse/
Human Chimera Isolation Kit (#19849, Stemcell Tech-
nologies, Vancouver, Canada). Resting human CD4+ T 
cells were negatively selected by magnetic separation 
from each sample essentially as described from human 
leukapheresis product [42] and from BLT mice [41]. 
Briefly, cells were incubated with antibodies against 
murine CD45 and TER119 and against human CD8, 
CD14, CD16, CD19, CD56, glycophorin A, CD41, HLA-
DR, CD25 (35 µl/ml) (Stemcell Technologies, Vancouver, 
Canada), CD31, and CD105 (0.5  µg/ml) (eBiosciences, 
San Diego, CA). Cells bound to antibody were removed 
by magnetic separation with EasySep (mice) or StemSep 
(human) custom isolation kit (Stemcell Technologies, 
Vancouver, Canada), and the flowthrough containing 
purified resting human CD4+ T cells was collected.
Measurement of RNA induction and quantitative viral 
outgrowth from resting cells
10–12 × 106 purified resting CD4+ T cells were cultured 
in media alone (untreated) or panobinostat (20 nM) over-
night (18–20 h) for RNA induction, then aliquoted into 
wells containing 1 × 106 cells each. Total RNA was iso-
lated from each well using the Magmax 96 Total RNA 
isolation kit (Ambion, Austin, TX). Duplicate pools of 
cDNA were synthesized from DNase-treated, isolated 
RNA using the SuperScript III First-Strand Synthesis 
SuperMix kit (Invitrogen, Carlsbad, CA). Two additional 
duplicate wells from each treatment condition did not 
include reverse transcriptase and served as control for 
DNA contamination. PCR amplification of cDNA was 
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performed in triplicate using the Biorad CFX 96 Real-
Time PCR detection system (Biorad, Hercules, CA) with 
previously published primers and probe [43]. A standard 
curve was generated for each PCR reaction using cDNA 
synthesized from in vitro-transcribed RNA where the p5′ 
plasmid served as template [44]. Results of the triplicate 
PCR replicates were averaged.
Purified resting cells were maintained in the presence 
of 15 nM efavirenz or 4 µM abacavir, and 1 µM raltegra-
vir, for 24 h prior to stimulation in limiting dilution with 
DMSO (0.0002  %, untreated), panobinostat (20  nM), or 
phytohemagglutinin (PHA, 1 µg/ml) for QVOA [42]. The 
frequency of infectious units per million or per billion 
resting human CD4+ T cells was calculated as a maxi-
mum likelihood estimate (or median posterior estimate if 
all wells were negative) using an in-house IUPM calcula-
tor and IUPMStats v.1.0 [45].
Generation of BLT humanized mice
BLT mice were generated as described previously [46]. 
6- to 8-week-old NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ, 
stock #5557, The Jackson Laboratory, Bar Harbor, ME) 
mice were sublethally irradiated, implanted with human 
thymus and liver tissue, and transplanted with autolo-
gous human liver CD34+ cells (Advanced Bioscience 
Resources, Alameda, CA); then they were monitored 
for human reconstitution in peripheral blood by flow 
cytometry [41, 46, 47]. All BLT mice (n =  21) used for 
these experiments contained an average of 51.6 % ± 17.7 
SD human CD45+ cells in the peripheral blood, of which 
60.3  %  ±  25.1 SD expressed CD3 on their cell surface. 
74.7 % ± 9.3 SD of human CD3+ cells expressed human 
CD4.
Analysis of histone acetylation
After uninfected human PBMCs were exposed in  vitro 
for 6 h to panobinostat, H3 acetylation was measured by 
flow cytometry as previously described [48].
H4 acetylation in cells from BLT tissues was assessed 
by ELISA. Mononuclear cells from each tissue were iso-
lated as previously described [46, 47]. Total cell num-
bers harvested from each tissue are summarized as 
follows: average 1.4 × 107 ± 5.3 × 106 SD bone marrow, 
1.5 ×  107 ±  5.9 ×  106 SD liver, 4.3 ×  106 ±  2.0 ×  106 
SD lung, 1.5  ×  106  ±  1.1  ×  106 SD lymph node, 
1.4 × 107 ± 7.3 × 106 SD spleen, 9.7 × 107 ± 1.0 × 108 
SD thymic organoid. Cell aliquots were pelleted and 
resuspended in 200 µl 1 % Triton X-100 (#X100, Sigma-
Aldrich, St. Louis, MO) in phosphate-buffered saline 
(PBS), then further diluted for measurement using 
3  % bovine serum albumin (BSA) in PBS. ELISA plates 
(Corning Costar, Corning, NY) were coated with 2  µg/
ml of anti-H4 monoclonal antibody (MBL, Woburn, MA) 
in 100  µl coating buffer (Sigma-Aldrich, St. Louis, MO) 
and incubated overnight at 4 °C. Plates were washed for 
5 min in 0.05 % Tween 20 (Sigma-Aldrich, St. Louis, MO) 
in PBS followed by blocking with 3 % BSA/PBS for 2 h to 
minimize non-specific binding. 100  µl cell lysates were 
added along with 50 µl 1:500 anti-H4K5/8/12/16 mono-
clonal antibody (Millipore, Billerica, MA) conjugated 
to alkaline phosphatase. Plates were incubated over-
night at 4 °C with gentle shaking followed by five washes 
with 0.05 % Tween 20/PBS and gentle shaking. 100 µl of 
Tropix CDP-Star Sapphire II substrate (Applied Biosys-
tems, Carlsbad, CA) was added to each well, and plates 
were incubated at room temperature for 20 min, followed 
by measurement of luminescence counts using an EnVi-
sion plate reader (Perkin Elmer, Waltham, MA).
HIV infection and treatment of BLT mice
BLT mice were infected by intravenous exposure to 
3 × 104 tissue culture infectious units HIV-1JR-CSF. Infec-
tion was monitored in peripheral blood by measuring 
plasma levels of HIV RNA as previously described (limit 
of detection = 750 copies per ml from 40 µl plasma sam-
ple volume) using one-step reverse transcriptase real-
time PCR (custom TaqMan Assays-by-Design, Applied 
Biosystems, Grand Island, NY) [32, 41]. Tissues were 
harvested and cells isolated as previously described [46, 
47]. Total cell numbers harvested from each tissue are 
summarized as follows: average 9.2  ×  107  ±  3.1  ×  107 
SD bone marrow, 1.6  ×  107  ±  7.6  ×  106 SD liver, 
5.9 × 106 ± 4.1 × 106 SD lung, 1.3 × 106 ± 1.6 × 106 SD 
lymph node, 1.5 × 106 ± 1.3 × 106 SD peripheral blood, 
1.8 × 107 ± 2.1 × 107 SD spleen, 1.0 × 108 ± 9.5 × 107 
SD thymic organoid. Cells were aliquoted for HIV DNA 
quantification (limit of detection = 4.5 copies), HIV RNA 
quantification (limit of detection = 4.5 copies), and flow 
cytometric analysis [46, 47]. Due to the use of carrier 
RNA during RNA extraction, HIV RNA measurements 
were normalized to the number of human CD4+ T cells. 
Flow cytometry data were collected using a BD FACS-
Canto cytometer and analyzed using BD FACSDiva soft-
ware v. 6.1.3 (BD Biosciences, San Jose, CA).
Antiretroviral therapy was administered to BLT mice 
via 1/2″ pellets of irradiated Teklad chow 2020X contain-
ing 1500 mg emtricitabine, 1,560 mg tenofovir disoproxil 
fumarate, and 600 mg raltegravir per kg (Research Diets, 
New Brunswick, NJ). Panobinostat (LBH589, #S1030, 
Selleckchem, Houston, TX) was dissolved in DMSO then 
diluted in 10  % (2-hydroxypropyl)-beta-cyclodextrin 
(#H107, Sigma-Aldrich, St. Louis, MO) (0.4  % DMSO 
final concentration) for intraperitoneal administration at 
a dose of 2  mg/kg. This dose was chosen after a higher 
dose of 5 mg/kg over 2 weeks (four doses, 3–4 days apart) 
resulted in 60 % (3/5) mortality.
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Statistical tests
All statistical tests were performed using an alpha level of 
0.05. Unpaired t test was utilized in Fig. 1a. Mann–Whit-
ney test was utilized in Figs. 1b, 2, 4, 5 and 6. Wilcoxon 
matched-pairs signed rank test was utilized in Fig.  1c. 
Graphs were generated in Graphpad Prism (v. 6).
Results
Induction of HIV expression with panobinostat 
from resting CD4+ T cells isolated from HIV‑infected 
patients on suppressive antiretroviral therapy
First, we assessed the effect of panobinostat on histone 
H3 acetylation in uninfected human PBMCs by flow 
cytometry. After 6 h incubation with panobinostat, there 
was a 3.0-fold increase in the level (mean fluorescence 
intensity) of histone acetylation in PBMCs with 10  nM 
panobinostat relative to DMSO control and a 3.5-fold 
increase with 20 nM panobinostat (p < 0.0001) (Fig. 1a).
In order to measure the effect of panobinostat on 
latently infected cells, we isolated resting CD4+ T cells 
from HIV-infected patients who were durably suppressed 
on ART for at least 6  months (Table  1). We incubated 
resting cells from three patients with 20  nM panobi-
nostat overnight and measured levels of cell-associated 
HIV RNA. The levels of HIV RNA increased by 6.2-fold 
(p < 0.001), 3.7-fold (p < 0.01), and 3.6-fold (p < 0.0001) 
in cells from patients 5, 6, and 8, respectively, in com-
parison to untreated cells (Fig. 1b). Resting CD4+ T cells 
from seven patients were also plated by limiting dilution 
and incubated with or without panobinostat (20 nM) to 
determine quantitative viral outgrowth. The mean infec-
tious units per billion cells detected with untreated cells 
was 389, and the mean with panobinostat-treated cells 
was 630 (p < 0.05) (Fig. 1c). Together, these results dem-
onstrate that panobinostat induced histone acetylation in 
primary human lymphocytes and allowed the recovery of 
HIV transcription and viral outgrowth from the resting 
CD4+ T cells of several HIV-infected aviremic patients. 
Based on these encouraging in  vitro results, we pro-
ceeded to evaluate the effect of panobinostat in vivo.
In vivo histone acetylation in tissues after treatment 
with panobinostat
Having characterized the ex vivo activity of panobinostat 
in primary human cells, we proceeded to perform a sys-
temic in vivo evaluation using BLT humanized mice. BLT 
mice were administered either vehicle (n = 5) or a single 
2 mg/kg dose of panobinostat (n = 3) by intraperitoneal 
injection. After 24  h, tissues were harvested, and cells 
were isolated for determination of histone acetylation 
by ELISA. The levels of histone acetylation were signifi-
cantly higher in five of the six tissues analyzed (p < 0.05 
Fig. 1 Effect of panobinostat on histone acetylation, HIV RNA, and 
viral outgrowth from patient cells. a Human PBMCs (n = 3) were 
incubated with panobinostat or DMSO control for 6 h, and histone 
H3 acetylation was measured by flow cytometry. b Resting CD4+ T 
cells were isolated from leukapheresis product obtained from three 
HIV-infected patients on suppressive antiretroviral therapy (outlined 
in Table 1), then pulsed with panobinostat (20 nM) or untreated. HIV 
RNA levels were measured from 10 to 12 individual wells (1 × 106 
cells each) by quantitative real-time PCR. c Resting CD4+ T cells 
were isolated from leukapheresis product obtained from seven 
HIV-infected patients on suppressive antiretroviral therapy (outlined 
in Table 1), then incubated with panobinostat (20 nM) or untreated. 
Viral outgrowth was measured by QVOA. Mean and SEM plotted with 
comparison by unpaired t test in a; Mann–Whitney test in b; Wilcoxon 
matched-pairs signed rank test in c: ns p > 0.05, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001. Blue bars/symbols denote control; pink 
and red bars/symbols denote panobinostat-treated
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in liver, lung, lymph node, spleen, and thymic orga-
noid); the difference was also higher in the bone mar-
row of panobinostat-treated mice with a trend toward 
significance (p = 0.07) (Fig. 2a). Taken together, a single 
2 mg/kg dose of panobinostat resulted in increased his-
tone acetylation 24 h later in all tissues analyzed, with a 
median RLU of 92,806 per million cells versus 5946 in 
the vehicle group, a 15.6-fold difference that was highly 
statistically significant (p  <  0.0001) (Fig.  2b). These 
results indicate that the administration of panobinostat 
resulted in systemic histone acetylation in  vivo in the 
tissues of BLT mice at this dose and timepoint, and that 
the determination of levels of histone acetylation can be 
used as a biomarker for histone deacetylase inhibition 
in vivo.
Analysis of the effect of panobinostat treatment 
in HIV‑infected, ART‑suppressed BLT mice
In order to evaluate the in  vivo effect of panobinostat 
on cell-associated HIV RNA, BLT mice (n  =  13) were 
infected with HIV-1JR-CSF (3  ×  104 tissue culture infec-
tious units) administered once via intravenous inocu-
lation (Fig.  3a). Three weeks after infection all animals 
had plasma viral loads greater than 1  ×  106 HIV RNA 
copies/ml (Fig.  3b). All infected mice were then admin-
istered ART consisting of raltegravir, emtricitabine, and 
tenofovir as indicated in the Methods section. As early as 
2 weeks after initiation of ART, plasma viral loads were 
below the limit of detection (750 copies/ml) (Fig. 3b) and 
remained undetectable for the duration of the experi-
ment. Six weeks after therapy initiation, suppressed 
mice were treated twice a week for 2  weeks with vehi-
cle (n  =  4) or panobinostat (2  mg/kg intraperitoneally, 
n = 9) (total four doses 3–4 days apart), in addition to the 
ART. At the end of 2 weeks (4 days after last panobinostat 
administration), tissues from control and panobinostat-
treated mice were harvested. Single cell suspensions were 
prepared from bone marrow, liver, lung, lymph node, 
spleen, thymic organoid, and peripheral blood, then ana-
lyzed by flow cytometry or used to isolate nucleic acids to 
quantitate HIV RNA and DNA levels by real-time PCR. 
There were no significant differences (p  >  0.05) in the 
median levels of cell-associated HIV RNA with regard to 
individual tissues between the control group and panobi-
nostat group (Fig.  4a). With all tissue data points taken 
together, the median level of cell-associated HIV RNA 
in the control group was 377 copies per 100,000 CD4+ T 
cells, compared to 193 copies per 100,000 CD4+ T cells 
in the panobinostat group. However, this difference was 
not statistically significant (p > 0.05) (Fig. 4b). Similar to 
the RNA results, there were no significant differences 
in median HIV DNA in individual tissues (Fig.  5a). The 
median copies HIV DNA per 100,000 CD4+ T cells of all 
tissues analyzed were 287 in the control group and 145 in 
the panobinostat group, but this difference was not sta-
tistically significant (p > 0.05) (Fig. 5b).  
Analysis of the effect of panobinostat on the levels 
of latently infected resting human CD4+ T cells
In order to evaluate the effect of panobinostat on the 
latent HIV reservoir, we pooled cells from all the dif-
ferent tissues obtained from each HIV-infected 
Fig. 2 Panobinostat administration induces systemic histone acetyla-
tion. NSG/BLT mice were administered panobinostat (2 mg/kg, n = 3) 
or vehicle (n = 5) intraperitoneally. After 24 h, tissues were harvested, 
and cells were isolated and resuspended in 1 % Triton-X/PBS. Cell 
lysates were analyzed for histone acetylation by ELISA. a Data from 
individual tissues. b Data from all tissues. Median and interquartile 
range plotted with comparisons by Mann–Whitney test: ns p > 0.05, 
*p < 0.05, ****p < 0.0001. Green circles denote control; mustard squares 
denote panobinostat-treated
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ART-suppressed mouse and isolated resting human 
CD4+ T cells. The resting phenotype of the isolated cells 
was assessed by flow cytometry. Isolated resting cells 
Fig. 3 Outline of panobinostat treatment of HIV-infected, ART-
suppressed BLT mice. a Experimental outline. BLT mice were infected 
intravenously with HIV-1JR-CSF. Starting at 2 weeks post exposure, mice 
were bled weekly for plasma viral load and flow cytometry analysis. 
Starting at 3 weeks post exposure, mice were administered antiret-
roviral therapy (ART) consisting of tenofovir disoproxil fumarate, 
emtricitabine, and raltegravir (light blue shading). After 6 weeks of 
ART, one group of mice was administered panobinostat at a dose of 
2 mg/kg intraperitoneally (red circles, n = 9) or vehicle (blue squares, 
n = 4), twice a week for 2 weeks, in addition to ART (light red shading). 
At the end of the experiment, mice were harvested, and cells were 
isolated for real-time PCR analysis and flow cytometry analysis. b 
Plasma viral load was measured by quantitative real-time PCR (limit 
of detection = 750 copies/ml, dashed line), and c  %CD4+ T cells was 
measured by flow cytometry. Mean values and SEM plotted
Fig. 4 Analysis of cell-associated HIV RNA levels in the tissues of 
infected, suppressed, panobinostat-treated BLT mice. BLT mice were 
infected with HIV-1JR-CSF, suppressed by antiretroviral therapy, and 
treated with panobinostat as described in Fig. 3. Cells were then iso-
lated from peripheral blood, bone marrow, liver, lung, lymph nodes, 
spleen, and thymic organoid for real-time quantitative PCR analysis of 
cell-associated HIV RNA levels. a Data from individual tissues. b Data 
from all tissues. Median and interquartile range plotted with compari-
sons by Mann–Whitney test: ns p > 0.05. Blue circles denote control; 
red squares denote panobinostat-treated
Table 1 Patient characteristics
Patient Age Sex Race Time on ART 
(months)
Time undetectable 
(months)
Current viral load  
(copies/ml)
Current CD4 
count (cells/µl)
1 27 Male White 74 70 <40 977
2 48 Male White 76 >6 <50 720
3 N/A Male White 38 32 <40 1145
4 57 Male White 121 83 <40 487
5 27 Male Black/African American 53 52 <40 798
6 61 Male Black/African American 235 110 <20 1302
7 53 Male White 193 76 <40 746
8 52 Male White 267 75 <40 439
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were characterized by their lack of CD25 and HLA-DR 
cell surface expression (Fig. 6a).
Consistent with their resting state, the levels of HIV 
RNA in cells obtained from these well suppressed ani-
mals were below the limit of detection in two out of four 
samples from vehicle-treated mice; the levels of HIV 
RNA in the other two samples had an average of 512 cop-
ies per 100,000 resting CD4+ T cells. The levels of HIV 
RNA were below the limit of detection in eight out of 
nine samples from panobinostat-treated mice. In the sin-
gle sample where we were able to quantitate HIV RNA 
in resting CD4+ T cells, it was 2100 copies per 100,000 
resting cells. These low levels of HIV RNA in resting cells 
are consistent with results from human samples [49] 
and further illustrate the fact that, as we have previously 
published [41], in our QVOA analysis we are indeed eval-
uating latently infected resting cells.
To determine the levels of latently infected cells con-
taining replication-competent proviruses, resting cells 
were first incubated with antiretroviral drugs over-
night, then washed and plated for QVOA using PHA for 
maximal stimulation, essentially as we have previously 
described [41]. Under our experimental conditions, the 
levels of latently infected cells per million resting CD4+ T 
cells (IUPM) between the control and the panobinostat-
treated groups were not statistically significantly different 
(p  >  0.05) (Fig.  6b). Together, these results demonstrate 
that panobinostat administration at this dosing did not 
result in statistically significant differences in levels of cell-
associated HIV RNA, HIV DNA, or latently infected cells 
in the tissues of HIV-infected, ART-suppressed BLT mice.
Discussion
Even with effective antiretroviral therapies, a cure for HIV 
remains elusive, due to persistent replication in lymphoid 
tissue sanctuaries and latent infection of resting CD4+ 
T cells. Strategies to reverse latency and clear persistent 
infection may bring us closer to a cure by (1) inducing 
HIV expression in latently infected cells through latency-
reversing agents, followed by (2) clearance of those cells 
mediated by viral cytopathic effects, immune clearance, 
or targeted cytotoxic agents. In this study, we evaluated 
the effect of histone deacetylase inhibitor panobinostat 
to modulate levels of cell-associated HIV RNA and HIV 
DNA as well as the size of the latent reservoir in BLT 
humanized mice. First, we observed that panobinostat 
treatment in vitro increased histone acetylation in unin-
fected human PBMCs and modestly induced HIV RNA 
expression in primary resting CD4+ T cells isolated from 
HIV-infected, ART-suppressed human subjects (Fig.  1). 
We also showed that ex vivo treatment with panobinostat 
induced outgrowth of replication-competent HIV from 
latently infected resting cells of several HIV-infected, 
ART-suppressed patients. Our results confirm and sup-
port previous results that panobinostat can reverse HIV 
latency in  vitro [20, 24]. Next, panobinostat demon-
strated histone deacetylase inhibition in BLT humanized 
mice: histone acetylation levels were significantly higher 
24  h post-dose in tissues obtained from panobinostat-
treated BLT mice compared to vehicle-treated animals 
(Fig. 2).
Following this demonstration of panobinostat bioactiv-
ity in BLT mice, we tested panobinostat in infected BLT 
mice suppressed with ART. We have previously shown 
that, in infected BLT mice, systemic levels of HIV RNA 
plateau 4 weeks after ART initiation [36]. In the current 
experiments, BLT mice received two additional weeks of 
ART to ensure that steady state levels had been reached. 
Fig. 5 Analysis of HIV DNA levels in the tissues of infected, sup-
pressed, panobinostat-treated BLT mice. BLT mice were infected with 
HIV-1JR-CSF, suppressed by antiretroviral therapy, and treated with 
panobinostat as described in Fig. 3. Cells were then isolated from 
peripheral blood, bone marrow, liver, lung, lymph nodes, spleen, and 
thymic organoid for real-time quantitative PCR analysis of HIV DNA 
levels. a Data from individual tissues. b Data from all tissues. Median 
and interquartile range plotted with comparisons by Mann–Whit-
ney test: ns p > 0.05. Blue circles denote control; red squares denote 
panobinostat-treated
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When we administered a 2-week course of panobinostat 
(four doses of 2 mg/kg, 3–4 days apart) to BLT mice that 
were infected with HIV and suppressed on ART, we 
did not observe a significant difference in levels of cell-
associated HIV RNA between panobinostat-treated and 
vehicle-treated BLT mice, 4  days after the last panobi-
nostat administration (Fig.  4). Given previous evidence 
that panobinostat activates transcription of HIV in vitro 
[20, 23, 24], we would have predicted an increase in cell-
associated HIV RNA in panobinostat-treated BLT mice. 
However, we have shown that, while ART dramatically 
reduces levels of cell-associated HIV RNA in BLT mice, 
actively infected cells persist and continue to express HIV 
RNA [36]. If panobinostat did produce a specific effect of 
HIV activation in a rare population of latently infected 
cells, the increase in HIV transcription from these cells 
Fig. 6 Analysis of panobinostat treatment on HIV latency in infected, suppressed BLT mice. BLT mice were infected with HIV-1JR-CSF, suppressed by 
antiretroviral therapy, and treated with panobinostat as described in Fig. 3. Resting human CD4+ T cells were isolated from the pooled tissues of 
each mouse, and analyzed by flow cytometry (a). Numbers of latently infected cells per million resting CD4+ T cells were determined by quantita-
tive viral outgrowth assay. Median and interquartile range plotted with comparisons by Mann–Whitney test: ns p > 0.05. Blue circles denote control; 
red squares denote panobinostat-treated
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appeared to be unobservable in the context of persistent 
HIV RNA expression within tissues, at the timepoint 
they were harvested.
If latency-reversing agents induce HIV expression in 
latently infected cells, then infected cells could be cleared 
by viral cytopathic effects or immune mechanisms; and 
if this effect were sufficiently profound, a reduction in 
cell-associated HIV DNA might be measurable. How-
ever, we did not observe a significant difference in the 
levels of cell-associated HIV DNA at harvest between 
panobinostat-treated compared to vehicle-treated BLT 
mice (Fig.  5). This result may be explained by the pre-
dominance of persisting actively infected cells [36] or of 
cells infected with defective proviruses [3, 50, 51] that 
do not encode viral antigens to allow clearance, thereby 
masking the potential reduction in cells carrying HIV 
DNA. Also, the quantification of HIV DNA in this study 
did not include measurement of integrated HIV DNA 
specifically. Some investigators have suggested that inte-
grated DNA might correlate more significantly with the 
frequency of latently infected resting CD4+ T cells [51]. 
The adaptation and validation of integrated HIV DNA 
quantification assays in fully suppressed BLT mice might 
be useful for an additional measure of the HIV reservoir 
in these models.
In order to more directly measure the frequency of 
cells containing latent, replication-competent HIV, we 
isolated resting human CD4+ T cells from the mice and 
utilized a QVOA, and a significant difference was not 
observed between the panobinostat- and vehicle-treated 
groups (Fig. 6). Based on the results presented in Fig. 1c 
showing approximately 500 infectious units per billion 
cells, the size of the latent reservoir in humanized mice 
might appear to be one order of magnitude greater than 
in humans. We should note that the amount of viral out-
growth from the human samples in Fig.  1c were meas-
ured after no treatment or after panobinostat treatment. 
These results do not reflect the total level of latent infec-
tion which would be measured after maximal stimulation 
by PHA treatment. The amount of viral outgrowth from 
the humanized mouse samples in Fig. 6b were measured 
after maximal stimulation by PHA treatment which likely 
explains the difference.
It should be noted that, while humanized mice are 
advantageous for studying HIV persistence in tissues, 
the limited amount of peripheral blood that can be col-
lected makes it impractical to study the peripheral blood 
latent reservoir. Therefore, our data reflect tissue reser-
voirs, in contrast to the peripheral blood reservoirs typi-
cally measured in patients. Also, although we did not 
measure histone acetylation levels directly in BLT ART-
suppressed mice, an increase in histone acetylation was 
demonstrated in uninfected mice in Fig. 2, and the ability 
of panobinostat to induce histone acetylation in humans 
undergoing ART has been previously demonstrated [24]. 
Notwithstanding, these results are similar to and com-
plement those in previously reported clinical trial results 
of panobinostat in HIV patients [24]; and they could be 
explained by insufficient induction of latent proviral 
genomes, insufficient clearance of latently infected cells, 
or a combination of the two.
One important aspect of the kick and kill approach 
to eradication is the implementation of effective killing 
strategies. Recent evidence suggests that panobinostat 
might alter cytotoxic T lymphocyte activity. Some groups 
have published observations that HDAC inhibitors may 
enhance the effector responses of CD8+ T cells [52–55], 
while others have observed that HDAC inhibitors may 
reduce the ability of CD8+ T cells to clear HIV-infected 
cells [56]. It will be of great interest in future studies to 
investigate the functional ability of CD8+ T cells to clear 
HIV-1 infected cells in vivo and the possible confounding 
effect of latency-reversing agents.
Nevertheless, the lack of a quantifiable response to 
panobinostat in this model is consistent with the limited 
increases observed in vitro, specifically in the induction of 
HIV replication from latently infected resting CD4+ T cells 
as demonstrated in the QVOA utilizing highly relevant 
patient samples. It is possible that a modified dosing or 
sampling regimen may reveal efficacy in our system, and 
this will require further study. Targeted cytotoxic agents 
[36, 57, 58] may be necessary as well to enable clearance. 
Additionally, alternative HDACis, such as romidepsin [21, 
59–62], or combinations of HDACis with other latency-
reversing agents may further enhance HIV reactivation 
[23, 63] and should be tested in future experiments.
For example, NOD/Rag1null/IL2Rgammanull mice 
injected intrahepatically with human liver-derived 
CD34+ cells (NRG-hu mice) have been used to test 
the effect of a combination of inducers—vorinostat, 
I-BET151, αCTLA4—and broadly neutralizing antibod-
ies. A significant number (57  %) of mice treated with 
the combination of inducers and antibodies failed to 
rebound upon therapy interruption. Cell-associated HIV 
RNA and DNA were largely undetectable (11/13 and 
5/13, respectively) in the spleens of non-rebounders, but 
the frequency of latently infected cells was not quanti-
fied [64].
The data presented herein demonstrate one clear paral-
lel between what is observed in humans and BLT human-
ized mice. In humans, panobinostat treatment did not 
result in a measurable decrease in the levels of latently 
infected cells. Similarly, in BLT mice, we did not observe 
a difference in the levels of latently infected cells between 
panobinostat-treated and vehicle-treated animals. The 
fact that treatment with a single latency-reversing agent 
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did not result in measurable reductions in the levels of 
latently infected cells in humans or BLT humanized mice 
serves to highlight the need for the evaluation of latency-
reversing agent combinations. The implementation of 
therapeutic interventions that couple suppressive ART 
with combinations of latency-reversing agents requires 
a rational and comprehensive approach where the indi-
vidual contribution of each agent alone is evaluated, and 
animal models that reflect the human condition will be 
useful for accelerating this progress towards an HIV cure 
[65].
Conclusion
We have performed a systemic in  vivo analysis in BLT 
humanized mice of the effect of panobinostat on his-
tone acetylation and on cell-associated HIV RNA, 
DNA, and latent infection. After panobinostat treat-
ment, we observed robust levels of systemic histone 
acetylation in BLT mice. However, we did not observe 
a statistically significant difference in the levels of cell-
associated HIV RNA or HIV DNA in HIV-infected, 
ART-suppressed BLT mice. These results are consistent 
with the modest effects of panobinostat noted in  vitro 
and in HIV-infected patients. Consistent with the 
results obtained in humans, in BLT mice panobinostat 
administration did not result in a decrease in the levels 
of latently infected resting CD4+ T cells. Together, the 
results obtained in both systems suggest that combina-
tion therapies may be necessary to reverse latency and 
enable clearance.
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